In last trading session, Enzo Biochem, Inc. (NYSE:ENZ) saw 1,274,588 shares changing hands with its beta currently measuring 0.71. Company’s recent per share price level of $2.16 trading at -$0.45 or -17.24% at ring of the bell on the day assigns it a market valuation of $103.44 Million. That closing price of ENZ’s stock is at a discount of -124.54% from its 52-week high price of $4.85 and is indicating a premium of 27.78% from its 52-week low price of $1.56. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 296.41 Million shares which gives us an average trading volume of 471.87 Million if we extend that period to 3-months.

For Enzo Biochem, Inc. (ENZ), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 0. Splitting up the data highlights that, out of 1 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 1 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.

Enzo Biochem, Inc. (NYSE:ENZ) trade information

In the face of being in the red today for losing -17.24%, in the last five days ENZ remained trading in the green while hitting it’s week-highest on Tuesday, Oct 13 when the stock touched $2.68-1 price level, adding 19.4% to its value on the day. Enzo Biochem, Inc.’s shares saw a change of -17.87% in year-to-date performance and have moved -3.57% in past 5-day. Enzo Biochem, Inc. (NYSE:ENZ) showed a performance of -4.42% in past 30-days. Number of shares sold short was 2.25 Million shares which calculate 0 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $5.5 to the stock, which implies a rise of 154.63% to its current value. Analysts have been projecting $5.5 as a low price target for the stock while placing it at a high target of $5.5. It follows that stock’s current price would jump +154.63% in reaching the projected high whereas dropping to the targeted low would mean a loss of 154.63% for stock’s current value.

Enzo Biochem, Inc. (ENZ) estimates and forecasts

1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $20.92 Million for the same. And 0 analysts are in estimates of company making revenue of $20.21 Million in the next quarter that will end in October 01, 2019. Company posted $24.45 Million of sales in current quarter a year earlier. Analysts are expecting this quarter sales to drop by -14.5%.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 17.3% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 121.6% while estimates for its earnings growth in next 5 years are of 0%

Enzo Biochem, Inc. (NYSE:ENZ)’s Major holders

Insiders are in possession of 7.71% of company’s total shares while institution are holding 68.48% percent of that, with stock having share float percentage of 74.19%. Investors also watch the number of corporate investors in a company very closely, which is 111 institutions for Enzo Biochem, Inc. that are currently holding shares of the company. Harbert Fund Advisors, Inc. is the top institutional holder at ENZ for having 5.62 Million shares of worth $12.59 Million. And as of June 29, 2020, it was holding 11.74% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 3.56 Million shares on June 29, 2020. The number of shares represents firm’s hold over 7.42% of outstanding shares, having a total worth of $7.96 Million.

On the other hand, Evermore Global Value Fd and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 2876107 shares of worth $6.44 Million or 6.01% of the total outstanding shares. The later fund manager was in possession of 1.59 Million shares on June 29, 2020, making its stake of worth around $3.55 Million in the company or a holder of 3.31% of company’s stock.